ConductScience.org, home

Comparison · NCT00010803-57cceaa8

Ginkgo Biloba vs Placebo: Number of Participants With Incident Dementia

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ginkgo Biloba vs Placebo: Number of Participants With Incident Dementia. Trial comparisons, record NCT00010803-57cceaa8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00010803-57cceaa8

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1790.1610.199wilson
Risk in group 20.1610.1440.181wilson
Risk difference, group 1 minus group 20.0179-0.008760.0445newcombe hybrid score
Risk ratio, group 1 over group 21.110.951.3log
Odds ratio, group 1 over group 21.130.941.37log
Number needed to treat, for one more participant with the outcome on Ginkgo Biloba than on Placebo56from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ginkgo Biloba120 mg twice daily, total 240 mg2771,545OG000
Group 2PlaceboPlacebo 1 pill twice a day2461,524OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Incident Dementia
Description
All cause dementia based on DSM-IV criteria as determined by an expert panel of clinicians using an adjudication process. A full neuropsychological battery was administered annually, or at 6 month visit if there was a diagnosis of dementia or initiation of medication for dementia by private physician, or change in Modified Mini Mental State Exam (3MSE), Clinical Dementia Rating (CDR), or Alzheimer Disease Assessment Scale (ADAS-Cog). Decline on tests scores based on an algorithm resulted in a neurological exam and brain imaging. These data were used in the adjudication process.
Time frame
Brief neuropsychological testing every 6 months, detailed testing annually, average 6.1 years follow up
Population
Subjects developing incident dementia during trial in each group, intention to treat (ITT).

Source ClinicalTrials.gov

Trial

Title
Ginkgo Biloba Prevention Trial in Older Individuals
NCT number
NCT00010803
Phases
PHASE3
Conditions
Dementia, Alzheimer's Disease
Interventions
Ginkgo biloba, Placebo
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
Results first posted
2010-09-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00010803-57cceaa8